Viking Therapeutics (VKTX) Cash & Equivalents (2014 - 2026)

Viking Therapeutics has disclosed Cash & Equivalents across 13 years of filings, most recently posting $118.1 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $118.1 million, up 211.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $118.1 million (up 211.32% YoY), and the FY2025 annual result was $165.8 million, up 521.57% from the prior year.
• Cash & Equivalents came in at $118.1 million for Q1 2026 at Viking Therapeutics, down from $165.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $195.6 million in Q1 2024 to a low of $18.4 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $50.3 million (2024), against an average of $79.4 million.
• Across the five-year window, Cash & Equivalents jumped 1629.43% in 2022 and slumped 89.72% in 2023, its largest moves.
• Viking Therapeutics' Cash & Equivalents stood at $36.6 million in 2022, then surged by 51.55% to $55.5 million in 2023, then plunged by 51.95% to $26.7 million in 2024, then soared by 521.57% to $165.8 million in 2025, then fell by 28.76% to $118.1 million in 2026.
• The last three Cash & Equivalents figures came in at $118.1 million (Q1 2026), $165.8 million (Q4 2025), and $100.4 million (Q3 2025), per Business Quant data.